Friday Mar 7
Perrigo Company PLC Price Target Increased to $190.00 by Analysts at Ubs Ag
The firm currently has a "buy" rating on the stock. UBS AG's price objective would suggest a potential upside of 15.52% from the stock's previous close.
Perrigo Company PLC Receives "Overweight" Rating from Morgan Stanley
's stock had its "overweight" rating reaffirmed by equities research analysts at Morgan Stanley in a research note issued to investors on Monday, American Banking News reports.
Perrigo Company plc and Transition Therapeutics Modify Development...
The Company also announced a investment by Perrigo to acquire approximately 7% of Transition's common shares.
Allegan walking trail funded by Bridgeport Apartments, Perrigo and local governments
The Allegan City Council last week contracted with engineering firm Prein & Newhof, of Grand Rapids, to design a trail along Hooker Road.
Perrigo Rating Lowered to Sell at Jefferson Research
Perrigo traded down 0.40% on Friday, hitting $150.16. The stock had a trading volume of 117,488 shares.
Transition Therapeutics Inc. Announces Second Quarter Fiscal 2014 Financial Results
With this acquisition, Perrigo acquired all the rights and obligations of Elan under the collaboration agreement with Waratah for the development and commercialization of ELND005; - Transition announced that their licensing partner Elan had dosed the first patient in a Phase 2a clinical study of ELND005 in Down Syndrome; - Transition announced that ... (more)